HK1128917A1 - 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity - Google Patents

5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity

Info

Publication number
HK1128917A1
HK1128917A1 HK09107080.7A HK09107080A HK1128917A1 HK 1128917 A1 HK1128917 A1 HK 1128917A1 HK 09107080 A HK09107080 A HK 09107080A HK 1128917 A1 HK1128917 A1 HK 1128917A1
Authority
HK
Hong Kong
Prior art keywords
diaminopyrazolo
pde
pyrimidines
inhibiting activity
inhibiting
Prior art date
Application number
HK09107080.7A
Other languages
English (en)
Inventor
Andrew Simon Bell
David Graham Brown
Kevin Neil Dack
David Nathan Abraham Fox
Ian Roger Marsh
Andrew Ian Morrell
Michael John Palmer
Carol Ann Winslow
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HK1128917A1 publication Critical patent/HK1128917A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK09107080.7A 2003-11-24 2009-08-03 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity HK1128917A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0327319.0A GB0327319D0 (en) 2003-11-24 2003-11-24 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
HK1128917A1 true HK1128917A1 (en) 2009-11-13

Family

ID=29764364

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07105414.0A HK1099286A1 (en) 2003-11-24 2007-05-22 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity
HK09107080.7A HK1128917A1 (en) 2003-11-24 2009-08-03 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK07105414.0A HK1099286A1 (en) 2003-11-24 2007-05-22 5,7-diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity

Country Status (44)

Country Link
EP (1) EP1689751B1 (xx)
JP (1) JP4056015B2 (xx)
KR (2) KR100893999B1 (xx)
CN (4) CN101362764B (xx)
AP (1) AP2227A (xx)
AR (1) AR046711A1 (xx)
AT (1) ATE485297T1 (xx)
AU (1) AU2004290643B2 (xx)
BR (1) BRPI0416869A (xx)
CA (1) CA2546987C (xx)
CR (1) CR8416A (xx)
CY (1) CY1110933T1 (xx)
DE (1) DE602004029705D1 (xx)
DK (1) DK1689751T3 (xx)
EA (1) EA011772B1 (xx)
EC (1) ECSP066580A (xx)
ES (1) ES2351622T3 (xx)
GB (1) GB0327319D0 (xx)
GE (1) GEP20084528B (xx)
HK (2) HK1099286A1 (xx)
HR (1) HRP20100651T1 (xx)
IL (1) IL175433A (xx)
IS (1) IS8406A (xx)
MA (1) MA28172A1 (xx)
ME (1) ME01216B (xx)
MX (1) MXPA06005914A (xx)
MY (1) MY140872A (xx)
NL (1) NL1027568C2 (xx)
NO (1) NO336526B1 (xx)
NZ (1) NZ548097A (xx)
OA (1) OA13289A (xx)
PA (1) PA8617701A1 (xx)
PE (1) PE20051061A1 (xx)
PL (1) PL1689751T3 (xx)
PT (1) PT1689751E (xx)
RS (1) RS51556B (xx)
SG (1) SG133614A1 (xx)
SI (1) SI1689751T1 (xx)
TN (1) TNSN06154A1 (xx)
TW (1) TWI265031B (xx)
UA (1) UA81994C2 (xx)
UY (1) UY28625A1 (xx)
WO (1) WO2005049616A1 (xx)
ZA (1) ZA200602899B (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
JP5094398B2 (ja) 2004-09-20 2012-12-12 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環式誘導体およびステアロイル−ＣｏＡデサチュラーゼのメディエータとしてのそれらの使用
CA2585557C (en) * 2004-10-28 2009-08-18 Pharmacia & Upjohn Company Llc Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
NL1029244C2 (nl) * 2005-06-10 2006-12-12 Ronald Silfried Marlin Middel ter vergroting van het mannelijk geslachtsorgaan.
DE102005050377A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
US7601713B2 (en) 2005-12-15 2009-10-13 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
WO2008132589A1 (en) * 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin
WO2009050554A2 (en) * 2007-10-19 2009-04-23 Pfizer Inc. Treatment of central nervous system disorders
DE102008063992A1 (de) * 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
EP2751116B1 (en) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014045162A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
JP6162820B2 (ja) 2012-12-19 2017-07-12 ファイザー・インク 炭素環式および複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
CA2897678A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
WO2015049616A1 (en) 2013-10-04 2015-04-09 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
JP2017500333A (ja) * 2013-12-20 2017-01-05 バイエル・ファルマ・アクティエンゲゼルシャフト グルコース輸送阻害剤
EP3126361B1 (en) 2014-04-01 2019-11-06 Pfizer Inc Chromene and 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
JP6554116B2 (ja) * 2014-04-04 2019-07-31 ハー・ルンドベック・アクチエゼルスカベット Ｐｄｅ１阻害剤としてのハロゲン化キナゾリン−ｔｈｆ−アミン
MD20160105A2 (ro) 2014-04-10 2017-03-31 Pfizer Inc. 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser
KR102522832B1 (ko) * 2014-12-08 2023-04-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 호흡기 세포융합 바이러스 （ｒｓｖ）의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 피라졸로［１，５―ａ］피리미딘 유도체
EP3253755B1 (en) 2015-02-03 2020-08-26 Pfizer Inc Novel cyclopropabenzofuranyl pyridopyrazinediones
CN107787322B (zh) 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
AU2017223132B2 (en) 2016-02-23 2019-12-05 Pfizer Inc. 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
HUE054857T2 (hu) 2016-07-01 2021-10-28 Pfizer 5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére
DK3642202T3 (da) 2017-06-22 2023-01-30 Pfizer Dihydro-pyrrolo-pyridin-derivater
CN112154145B (zh) 2018-03-23 2023-10-17 辉瑞大药厂 哌嗪氮杂螺衍生物
CA3100923A1 (en) 2018-06-04 2019-12-12 Exscientia Ltd Pyrazolopyrimidine compounds as adenosine receptor antagonists
WO2020041741A1 (en) * 2018-08-24 2020-02-27 Terns, Inc. Thyroid hormone receptor beta agonist compounds
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
GB9823102D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
AU5995699A (en) * 1998-10-23 2000-05-15 Bunnage, Mark Edward Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
DE10031236A1 (de) * 2000-06-27 2002-01-10 Qiagen Gmbh Verwendung von Carbonsäuren und anderen Additiven in Kombination mit kationischen Verbindungen zur Stabilisierung von Nukleinsäuren in biologischen Materialien
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
EP1348707B1 (en) * 2002-03-28 2010-08-25 Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
JP4015176B2 (ja) * 2003-04-29 2007-11-28 ファイザー・インク 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類

Also Published As

Publication number Publication date
WO2005049616A1 (en) 2005-06-02
ECSP066580A (es) 2006-12-20
CN101362765B (zh) 2011-02-02
TWI265031B (en) 2006-11-01
RS51556B (en) 2011-06-30
IS8406A (is) 2006-04-10
UA81994C2 (xx) 2008-02-25
AU2004290643A1 (en) 2005-06-02
GB0327319D0 (en) 2003-12-24
CN101362764A (zh) 2009-02-11
UY28625A1 (es) 2005-06-30
EP1689751B1 (en) 2010-10-20
EA011772B1 (ru) 2009-06-30
GEP20084528B (en) 2008-11-10
TW200520758A (en) 2005-07-01
EA200600677A1 (ru) 2006-12-29
AP2006003591A0 (en) 2006-04-30
ES2351622T3 (es) 2011-02-08
CN1882591B (zh) 2011-08-10
NL1027568A1 (nl) 2005-05-26
PL1689751T3 (pl) 2011-03-31
AU2004290643B2 (en) 2008-08-07
NL1027568C2 (nl) 2005-11-30
JP4056015B2 (ja) 2008-03-05
NO20062950L (no) 2006-08-23
KR100893999B1 (ko) 2009-04-20
JP2007512314A (ja) 2007-05-17
TNSN06154A1 (fr) 2007-11-15
CN101362764B (zh) 2011-04-20
PA8617701A1 (es) 2005-08-04
HK1099286A1 (en) 2007-08-10
CA2546987A1 (en) 2005-06-02
ME01216B (me) 2013-03-20
AR046711A1 (es) 2005-12-21
DK1689751T3 (da) 2011-01-17
CN1882591A (zh) 2006-12-20
CN101362765A (zh) 2009-02-11
SG133614A1 (en) 2007-07-30
KR100848216B1 (ko) 2008-07-24
KR20070026334A (ko) 2007-03-08
ZA200602899B (en) 2007-07-25
CY1110933T1 (el) 2015-06-10
CR8416A (es) 2006-11-15
KR20080052666A (ko) 2008-06-11
MY140872A (en) 2010-01-29
ATE485297T1 (de) 2010-11-15
IL175433A0 (en) 2006-09-05
AP2227A (en) 2011-03-29
SI1689751T1 (sl) 2011-01-31
WO2005049616A8 (en) 2006-06-01
DE602004029705D1 (de) 2010-12-02
CN101647802A (zh) 2010-02-17
NO336526B1 (no) 2015-09-21
PT1689751E (pt) 2010-11-29
NZ548097A (en) 2008-12-24
BRPI0416869A (pt) 2007-03-27
MXPA06005914A (es) 2006-06-27
MA28172A1 (fr) 2006-09-01
EP1689751A1 (en) 2006-08-16
PE20051061A1 (es) 2005-12-12
HRP20100651T1 (hr) 2011-01-31
IL175433A (en) 2011-08-31
CA2546987C (en) 2009-05-12
OA13289A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
IL175433A0 (en) 5,7 diaminopyrazolo [4,3-d] pyrimidines with pde-5 inhibiting activity
IL182099A0 (en) Piperidinylamino-thieno[2,3-d] pyrimidine compounds
EP1599482A4 (en) PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
PL376916A1 (pl) Pochodne pirymido [4,5-d] pirymidyny o działaniu przeciwrakowym
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
TWI365189B (en) Novel pyrrolo[3,2-d]pyrimidin-4-one derivatives
EG24843A (en) Herbicidal pyrimidines
HK1088893A1 (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
EP1653969A4 (en) PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
HK1091488A1 (en) Pyrimidine derivatives
ZA200604960B (en) Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-A]pyrimidin-6-onederivatives
AP2002002543A0 (en) Pyrrolo Ä2,3-dÜ pyrimidine compounds
IL172098A0 (en) Triazolopyrimidines
IL172848A0 (en) 2-substituted pyrimidines
IL172359A0 (en) Triazolopyrimidines
PL353366A1 (en) Pyrazolo[4,3-d]pyrimidines
PL358551A1 (en) 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines
PL372989A1 (en) Triazolopyrimidines
MXPA03004498A (es) Uso de pirazolo (4,3-d)pirimidinas.
IL172845A0 (en) 2-substituted pyrimidines
TWI372760B (en) A pyrazolo[1,5-a]pyrimidine compound
GB0323137D0 (en) 2,4,6- Trisubstituted pyrimidines and their different uses
IL173347A0 (en) 7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-a] PYRIMIDINES
TJ431B (en) 2-Brom-7-methil-5-oxo-5h-1,3,4-thyodyazol-(3,2-a)pyrimidin, has antibacterial activity
SI1567522T1 (sl) Pirimidinske spojine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181112